Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Two-stage, Single-arm Phase II Study of Zongertinib Plus Fulvestrant in Participants With Hormone Receptor-positive/HER2-negative Advanced Breast Cancer Harboring HER2 Mutations.

NCT07619066 is registered in ClinicalTrials.gov with MedSIR as lead sponsor.

NCT NCT07619066
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07619066 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Two-stage, Single-arm Phase II Study of Zongertinib Plus Fulvestrant in Participants With Hormone Receptor-positive/HER2-negative Advanced Breast Cancer Harboring HER2 Mutations.
Lead sponsor
MedSIR
Phase
Phase 2
Overall status
Not yet recruiting
Start date
October 4, 2026
Completion date
November 28, 2028
Enrollment
25 (estimated)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

advanced breast cancer, her2 mutation, hormone receptor positive / her2-negative breast cancer